U S Federal Circuit Court of Appeals Fully Upholds Eisai s Favorable Ruling in Aciphex Patent Infringement Lawsuit Against Teva Pharmaceuticals and Dr Reddy s Laboratories: related news

U.S. Federal Circuit Court of Appeals Fully Upholds Eisai's Favorable Ruling in Aciphex Patent Infringement Lawsuit Against Teva Pharmaceuticals and Dr. Reddy's Laboratories

TOKYO and WOODCLIFF LAKE, N.J., July 21, 2008 /PRNewswire/ -- With respect to Eisai's patent infringement lawsuit against Teva Pharmaceuticals and Dr. Reddy's Laboratories concerning Aciphex(R) (generic name: rabeprazole sodium tablets, Product Name in Japan: Pariet(R)), Eisai Co., Ltd. and its U.S. subsidiary Eisai Inc. (collectively "Eisai") today announce that the United States Court of Appeals for the Federal Circuit has affirmed both the United States District Court for the Southern District of New York's summary judgment ruling on the validity of Eisai's composition of matter patent and its ruling on the enforceability of the composition of matter patent.

U.S. FEDERAL CIRCUIT COURT OF APPEALS FULLY UPHOLDS EISAI'S FAVORABLE RULING IN ACIPHEX PATENT INFRINGEMENT LAWSUIT AGAINST TEVA PHARMACEUTICALS AND DR. REDDY'S LABORATORIES

EISAI'S FAVORABLE RULING IN ACIPHEX® PATENT INFRINGEMENT LAWSUIT AGAINST TEVA PHARMACEUTICALS AND DR. REDDY'S LABORATORIES

German Court Rules Qualcomm GSM Patent Claim Against Nokia Invalid

The German Federal Patent Court ruled today that Qualcomm’s GSM patent case against Nokia (NYSE: NOK) is invalid, Reuters reports. This is the third court to conclude that the American chipmaker’s patent claims against Nokia are “without merit,” said the Finnish handset maker. The United Kingdom High Court, and the U.S. International Trade Commission have also ruled that Qualcomm’s GSM patent claims against Nokia to be invalid. The two will meet again in German court in October, when a second Qualcomm (NSDQ: QCOM) patent case will be heard. The news comes on the same day that Qualcomm and Nokia are to meet in a Deleware Court over its ongoing patent dispute.

U.S. Federal Circuit Court of Appeals Rules Patent for Aciphex Valid and Enforceable

RARITAN, N.J., July 21, 2008, 2008 /PRNewswire/ -- PriCara,(TM) Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., announced today that the U.S. Federal Circuit Court of Appeals affirmed the judgments of the United States District Court for the Southern District of New York that the patent for ACIPHEX(R) (rabeprazole sodium 20 mg tablets) is valid and enforceable.

EV Group Files Patent Infringement Lawsuit Against the 3M Company

EV Group (EVG), a leading supplier of wafer-bonding and lithography equipment for the advanced semiconductor and packaging, MEMS, silicon-on-insulator (SOI) and emerging nanotechnology markets, today announced that it has filed a patent infringement lawsuit in federal court of New York against the 3M Company ("3M"). The complaint alleges that 3M has infringed upon a U.S. Patent through the marketing and sale of the 3M Wafer Support System, which is used in the production of silicon wafers. The complaint seeks damages to compensate EVG for 3M's wrongful infringement and an injunction against 3M from all future infringement of the Patent.

EV Group Files Patent Infringement Lawsuit Against the 3M Company

ST. FLORIAN, Austria, July 14 /PRNewswire/ -- EV Group (EVG), a leading supplier of wafer-bonding and lithography equipment for the advanced semiconductor and packaging, MEMS, silicon-on-insulator (SOI) and emerging nanotechnology markets, today announced that it has filed a patent infringement lawsuit in federal court of New York against the 3M Company ("3M"). The complaint alleges that 3M has infringed upon a U.S. Patent through the marketing and sale of the 3M Wafer Support System, which is used in the production of silicon wafers. The complaint seeks damages to compensate EVG for 3M's wrongful infringement and an injunction against 3M from all future infringement of the Patent.

EV Group Files Patent Infringement Lawsuit Against the 3M Company

ST. FLORIAN, Austria, July 14 /PRNewswire/ -- EV Group (EVG), a leading supplier of wafer-bonding and lithography equipment for the advanced semiconductor and packaging, MEMS, silicon-on-insulator (SOI) and emerging nanotechnology markets, today announced that it has filed a patent infringement lawsuit in federal court of New York against the 3M Company ("3M"). The complaint alleges that 3M has infringed upon a U.S. Patent through the marketing and sale of the 3M Wafer Support System, which is used in the production of silicon wafers. The complaint seeks damages to compensate EVG for 3M's wrongful infringement and an injunction against 3M from all future infringement of the Patent.

EV Group Files Patent Infringement Lawsuit Against the 3M Company

ST. FLORIAN, Austria, July 14 /PRNewswire/ -- EV Group (EVG), a leading supplier of wafer-bonding and lithography equipment for the advanced semiconductor and packaging, MEMS, silicon-on-insulator (SOI) and emerging nanotechnology markets, today announced that it has filed a patent infringement lawsuit in federal court of New York against the 3M Company ("3M"). The complaint alleges that 3M has infringed upon a U.S. Patent through the marketing and sale of the 3M Wafer Support System, which is used in the production of silicon wafers. The complaint seeks damages to compensate EVG for 3M's wrongful infringement and an injunction against 3M from all future infringement of the Patent.

Watson Announces District Court Ruling in Naproxen Sodium Patent Suit

CORONA, Calif., Aug. 13 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. , a leading specialty pharmaceutical company, announced today that the United States District Court for the Southern District of Florida ruled today that Watson's Naproxen Sodium ER tablets, the generic version of Naprelan(R), infringes Elan's U.S. Patent No. 5,637,320 (the "'320 Patent"). The action, Elan Corporation Plc v. Andrx Pharmaceuticals, Inc., was initially brought by Elan in October 1998 following Andrx's filing of a paragraph IV Abbreviated New Drug Application for its product. In March 2002, the District Court ruled that Elan's '320 Patent was invalid. Subsequently, in May 2004, the United States Court of Appeals for the Federal Circuit reversed the District Court's finding of invalidity and remanded the case for further proceedings.

Watson Announces District Court Ruling in Naproxen Sodium Patent Suit

CORONA, Calif., August 13, 2008 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. , a leading specialty pharmaceutical company, announced today that the United States District Court for the Southern District of Florida ruled today that Watson's Naproxen Sodium ER tablets, the generic version of Naprelan(R), infringes Elan's U.S. Patent No. 5,637,320 (the "'320 Patent"). The action, Elan Corporation Plc v. Andrx Pharmaceuticals, Inc., was initially brought by Elan in October 1998 following Andrx's filing of a paragraph IV Abbreviated New Drug Application for its product. In March 2002, the District Court ruled that Elan's '320 Patent was invalid. Subsequently, in May 2004, the United States Court of Appeals for the Federal Circuit reversed the District Court's finding of invalidity and remanded the case for further proceedings.

Court: violating copyleft = copyright infringement

A federal appeals court has overruled a lower court ruling that, if sustained, would have severely hampered the enforceability of free software licenses. The lower court had found that redistributing software in violation of the terms of a free software license could constitute a breach of contract, but was not copyright infringement. The difference matters because copyright law affords much stronger remedies against infringement than does contract law. If allowed to stand, the decision could have neutered popular copyleft licenses such as the GPL and Creative Commons licenses. The district court decision was overturned on Wednesday by the United States Court of Appeals for the Federal Circuit.

Court: 'Violating Copyleft Is Copyright Infringement'

IconA federal appeals court has overruled a lower court ruling that, if sustained, would have severely hampered the enforceability of free software licenses. The lower court had found that redistributing software in violation of the terms of a free software license could constitute a breach of contract, but was not copyright infringement. The difference matters because copyright law affords much stronger remedies against infringement than does contract law. If allowed to stand, the decision could have neutered popular copyleft licenses such as the GPL and Creative Commons licenses. The district court decision was overturned on Wednesday by the United States Court of Appeals for the Federal Circuit.

The Research Foundation of State University of New York and Sigrity Filed Patent Infringement Lawsuit Against Ansoft/ANSYS

SANTA CLARA, Calif. (Business Wire) -- Sigrity, Inc., known for its power integrity and signal integrity software solutions for integrated circuits, IC packages and printed circuit boards, announced today that it filed a lawsuit with The Research Foundation of State University of New York against Ansoft Corp. and ANSYS, Inc. for infringement of U.S. Patent No. 5,504,423 ("the '423 patent"), titled "Method for Modeling Interactions in Multilayered Electronic Packaging Structures." The Research Foundation is the owner and Sigrity is the exclusive licensee of the '423 patent. The suit, pending in United States District Court in Albany New York, was filed on July 21, 2008 against Ansoft and alleges that Ansoft's products, including its SIwave product, infringe the '423 patent.

The Research Foundation of State University of New York and Sigrity Filed Patent Infringement Lawsuit Against Ansoft/ANSYS

SANTA CLARA, Calif., Aug 18, 2008 (BUSINESS WIRE) -- Sigrity, Inc., known for its power integrity and signal integrity software solutions for integrated circuits, IC packages and printed circuit boards, announced today that it filed a lawsuit with The Research Foundation of State University of New York against Ansoft Corp. and ANSYS, Inc. for infringement of U.S. Patent No. 5,504,423 ("the '423 patent"), titled "Method for Modeling Interactions in Multilayered Electronic Packaging Structures." The Research Foundation is the owner and Sigrity is the exclusive licensee of the '423 patent. The suit, pending in United States District Court in Albany New York, was filed on July 21, 2008 against Ansoft and alleges that Ansoft's products, including its SIwave product, infringe the '423 patent.

Energizer Holdings, Inc. Files Patent Infringement Complaint in Federal Court Against...

Energizer Holdings, Inc. Files Patent Infringement Complaint in Federal Court Against Spectrum Brands ST. LOUIS, July 28 /PRNewswire-FirstCall/ -- Energizer Holdings, Inc., (NYSE: ENR), and the Eveready Battery Company, Inc. have filed a Complaint with the United States District Court Western District of Wisconsin. The Complaint is against Spectrum Brands and alleges patent infringement of patents owned by Energizer. Energizer believes that Spectrum Brands infringe Energizer's US Patents 5,290,414 and 6,849,360 by importing and selling primary lithium batteries in the United States. The alleged infringing products are manufactured and imported from China and bear the Rayovac Lithium brand. They have recently been made available for sale by Spectrum Brands at a major US retailer.

Applied Nanotech Holdings, Inc. Announces Court Decision

Applied Nanotech Holdings, Inc. (OTCBB: APNT) announced that the U.S. Court of Appeals for the Fifth Circuit issued its opinion in its litigation with Canon, Inc. The appeals court in part affirmed, and in part reversed, the rulings of the district court. While the appeals court accepted, without deciding, the district court's decision that SED, Inc. as originally formed did not qualify as a Canon subsidiary, and that Canon had materially breached the contract, it found that termination of the license agreement was not an appropriate remedy. The appeals court also ruled that the restructured SED, Inc., which is 100% owned by Canon, now qualifies as a Canon subsidiary. The appeals court denied Applied Nanotech's appeal that the district court had improperly excluded certain evidence from the trial.

Applied Nanotech Holdings, Inc. Announces Court Decision

Applied Nanotech Holdings, Inc. (OTCBB: APNT) announced that the U.S. Court of Appeals for the Fifth Circuit issued its opinion in its litigation with Canon, Inc. The appeals court in part affirmed, and in part reversed, the rulings of the district court. While the appeals court accepted, without deciding, the district court's decision that SED, Inc. as originally formed did not qualify as a Canon subsidiary, and that Canon had materially breached the contract, it found that termination of the license agreement was not an appropriate remedy. The appeals court also ruled that the restructured SED, Inc., which is 100% owned by Canon, now qualifies as a Canon subsidiary. The appeals court denied Applied Nanotech's appeal that the district court had improperly excluded certain evidence from the trial.

DP6946 Patent Thickets and the Market for Innovation: Evidence from Settlement of Patent Disputes

We study how fragmentation of patent rights (‘patent thickets’) and the formation of the Court of Appeal for the Federal Circuit (CAFC) affected the duration of patent disputes, and thus the speed of technology diffusion through licensing. We develop a model of patent litigation which predicts faster settlement agreements when patent rights are fragmented and when there is less uncertainty about court outcomes, as was associated with the ‘pro-patent shift’ of CAFC. The model also predicts that the impact of fragmentation on settlement duration should be smaller under CAFC. We confirm these predictions empirically using a dataset that covers nearly all patent suits in U.S. federal district courts during the period 1975-2000. Finally, we analyze how fragmentation affects total settlement delay, taking into account both reduction in duration

Linear Technology says disappointed with Patent Appeals Court's opinion in one of two infringement cases against Advanced Analogic

(RTTNews) - Linear Technology Corp. (LLTC: News ), a manufacturer of linear integrated circuits, said Friday that it is disappointed with the ruling of Court of Appeals for the Federal Circuit in one of the two patent infringement lawsuits filed by the company against Advanced Analogic Technologies, Inc. (AATI: News ).

The Research Foundation of State University of New York and Sigrity Filed Patent...

The Research Foundation of State University of New York and Sigrity Filed Patent Infringement Lawsuit Against Ansoft/ANSYS SANTA CLARA, Calif.--(Business Wire)-- Sigrity, Inc., known for its power integrity and signal integrity software solutions for integrated circuits, IC packages and printed circuit boards, announced today that it filed a lawsuit with The Research Foundation of State University of New York against Ansoft Corp. and ANSYS, Inc. for infringement of U.S. Patent No. 5,504,423 ("the '423 patent"), titled "Method for Modeling Interactions in Multilayered Electronic Packaging Structures." The Research Foundation is the owner and Sigrity is the exclusive licensee of the '423 patent. The suit, pending in United States District Court in Albany New York, was filed on July 21, 2008 against Ansoft and alleges that Ansoft's products,

Allergan To Drop Patent Infringement Lawsuit Against Jan Marini Skin Research

July 21, 2008 (FinancialWire) Allergan Inc. (NYSE: AGN), which makes Botox and breast implants, said that it will drop a patent-infringement lawsuit against Jan Marini Skin Research after that company agreed to stop making certain types of eyelash conditioning products. Jan Marini is one of several defendants in a patent-infringement case in the U.S District Court for the Central District of California. The dismissal is based on Jan Marini acknowledgment of the validity of Allergan's relevant patents covering the use of certain drugs that promote eyelash enhancement. The company also said it would stop selling products containing the ingredients in question. Shares of Allergan fell 14 cents to close at $52.16 on Friday. FinancialWire is a fully independent, proprietary news wire service of Investrend Information (a division of Investrend

OPTi Receives Ruling in Markman Hearing in Patent Infringement Action Against Advanced Micro Devices, Inc.

PALO ALTO, Calif., BUSINESS WIRE -- OPTi Inc. (OTCBB:OPTI) today announced that the United States District Court for the Eastern District of Texas issued a ruling in the ongoing patent infringement action between OPTi Inc ("OPTi") and Advanced Micro Devices, Inc. ("AMD"). The ruling arises from a special proceeding required under U.S. patent law called a "Markman hearing," where both sides present their arguments to the court as to how they believe certain terms at issue in the lawsuit should be interpreted.

Patent Infringement Suit Against ProLink Without Merit

CHANDLER, Ariz., July 22 /PRNewswire-FirstCall/ -- ProLink Holdings Corp. , the world's leading provider of GPS - enabled golf management systems, responded today to a suit claiming patent infringement that was filed in the United States District Court for the Northern District of Illinois by GPS Industries, Inc. (GPSI) against its subsidiary ProLink Solutions, LLC, and other defendants. The suit alleges infringement of U.S. Patent No. 5,685,786 and U.S. Patent No. 5,438,518, and other matters. The Company believes that the suit is baseless and without merit. ProLink intends to defend itself vigorously, and will continue to pursue previously announced litigation against GPSI aggressively. Furthermore, ProLink also believes that it does not infringe either of '518 or '768 patents with its product and service offerings, and it is surprised

Patent Infringement Suit Against ProLink Without Merit

CHANDLER, Ariz., July 22 /PRNewswire-FirstCall/ -- ProLink Holdings Corp. (OTC Bulletin Board: PLKH), the world's leading provider of GPS - enabled golf management systems, responded today to a suit claiming patent infringement that was filed in the United States District Court for the Northern District of Illinois by GPS Industries, Inc. (GPSI) (OTC Bulletin Board: GPSN) against its subsidiary ProLink Solutions, LLC, and other defendants. The suit alleges infringement of U.S. Patent No. 5,685,786 and U.S. Patent No. 5,438,518, and other matters. The Company believes that the suit is baseless and without merit. ProLink intends to defend itself vigorously, and will continue to pursue previously announced litigation against GPSI aggressively. Furthermore, ProLink also believes that it does not infringe either of '518 or '768 patents with it

Patent Infringement Suit Against ProLink Without Merit

CHANDLER, Ariz., July 22 /PRNewswire-FirstCall/ -- ProLink Holdings Corp. (OTC Bulletin Board: PLKH - News), the world's leading provider of GPS - enabled golf management systems, responded today to a suit claiming patent infringement that was filed in the United States District Court for the Northern District of Illinois by GPS Industries, Inc. (GPSI) (OTC Bulletin Board: GPSN - News) against its subsidiary ProLink Solutions, LLC, and other defendants. The suit alleges infringement of U.S. Patent No. 5,685,786 and U.S. Patent No. 5,438,518, and other matters. The Company believes that the suit is baseless and without merit. ProLink intends to defend itself vigorously, and will continue to pursue previously announced litigation against GPSI aggressively.

Search took 0.80 seconds.